Diagnosis and Therapeutic Management of Ventricular Gangliogliomas: An Illustrated Review

Salge-Arrieta, Freddy J; Carrasco, Rodrigo; Rodríguez-Berrocal, Víctor; Vior-Fernández, Carlos; Lee, Paul; Pián, Héctor; Millán, J S Martínez-San; Ley-Urzáiz, Luis

doi:10.1016/j.wneu.2021.01.119

Cited by 2 publications

(5 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Subtotal resection (STR) was performed in 44% of the cases, gross total resection (GTR) in 26% of the cases, simple biopsy and partial removal in 15% of the cases. Adjuvant chemotherapy was reported in 7% of the cases after STR for a cerebellar anaplastic ganglioglioma [ 11 ] and a ganglioglioma of the fourth ventricle [ 9 ]. Adjuvant radiotherapy was found in 22% of the cases and specifically after STR of anaplastic ganglioglioma of the fourth ventricle [ 9 ], anaplastic ganglioglioma of the cerebellum [ 11 ], cerebellar ganglioblastoma [ 12 ], CPA ganglioblastoma [ 13 ] and cerebellar xanthoastrocytoma–pleomorphic ganglioglioma [ 14 ].…”

Section: Resultsmentioning

confidence: 99%

“…Adjuvant chemotherapy was reported in 7% of the cases after STR for a cerebellar anaplastic ganglioglioma [ 11 ] and a ganglioglioma of the fourth ventricle [ 9 ]. Adjuvant radiotherapy was found in 22% of the cases and specifically after STR of anaplastic ganglioglioma of the fourth ventricle [ 9 ], anaplastic ganglioglioma of the cerebellum [ 11 ], cerebellar ganglioblastoma [ 12 ], CPA ganglioblastoma [ 13 ] and cerebellar xanthoastrocytoma–pleomorphic ganglioglioma [ 14 ]. Finally, in 15% of the cases, disease recurrence occurred between 1 and 12 months after surgery (with a mean period of 11 months).…”

Section: Resultsmentioning

confidence: 99%

“…This systematic review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines [ 9 ], but it was not pre-registered. We performed a broad systematic literature search in the PubMed/Medline electronical database for all studies.…”

Section: Methodsmentioning

confidence: 99%

See 2 more Smart Citations

Infratentorial Relapsing Neuroglial Tumors in Adults: Management and Unsolved Issues—A Systematic Review

Brunasso,

Avallone,

Florena

et al. 2024

Brain Sciences

View full text Add to dashboard Cite

(1) Background: Gangliogliomas are rare tumors accounting for about 0.4% of all central nervous system tumors. They are usually located in the temporal lobes of children and young adults, though such tumors in the infratentorial region and adult-age patients rarely reported. (2) Methods: A systematic review on ganglioglioma with infratentorial location in the adult population was conducted in accordance with the PRISMA guidelines. A total of 275 articles were found, and 23 were included. Demographic data, the location and histology of the lesion, pre-operative neurological status, the type of surgery, recurrence, radiotherapy/chemotherapy adjuvant treatments, neurological outcomes and follow-up information were collected. We also presented an illustrative case. (3) Results: A total of 27 patients were included. In 51%, the location was the cerebellum; in 40%, it was the fourth ventricle; in 11%, it was brainstem; and in 4%, it was the cerebellopontine angle. STR was performed in 44%, GTR in 26% and biopsy in 15% of the cases. Adjuvant radiotherapy was found in 22% of cases. Disease recurrence occurred in 15% of patients between 1 and 12 months after surgery with a diagnosis of high-grade ganglioglioma, while in six cases, no disease recurrence was documented. (4) Conclusions: Infratentorial glioneuronal tumors are rare findings in the adult population. Histopathological characterization does not seem to fully reflect their true behavior. Future studies are warranted for better characterizing histopathological findings and treatment.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Infratentorial Relapsing Neuroglial Tumors in Adults: Management and Unsolved Issues—A Systematic Review

Brunasso,

Avallone,

Florena

et al. 2024

Brain Sciences

View full text Add to dashboard Cite

show abstract

“…Although adjuvant radiotherapy provides higher local control rates, 11 the low radiological progression rates of residual disease 3,10 and concerns about malignant transformation of gangliogliomas following radiotherapy 2,12,13 have promoted an active surveillance approach. 14 Adverse radiation effects, including vasculopathy and neurocognitive and endocrinological complications, usually make radiotherapy undesirable in the pediatric and young adult population. 15 The efficacy of systemic chemotherapy as an adjuvant therapy following STR or in recurrence is also unclear.…”

Section: Discussionmentioning

confidence: 99%

“…16 Standard chemotherapy regimens have shown limited benefit in extending progression-free survival 17 but may be beneficial in delaying radiotherapy in the pediatric population. 14,18 BRAF V600E mutations have been detected in approximately 50% of gangliogliomas 19,20 and are associated with poor outcomes following conventional radiation treatment and chemotherapy, suggesting that BRAF V600E-mutated gangliogliomas may constitute a different tumor type. 19,21 Positive responses following targeted monotherapy or combination therapies with BRAF inhibitors have been reported in case reports on adult and pediatric patients with low-grade and anaplastic gangliogliomas.…”

Section: Discussionmentioning

confidence: 99%

Radiological and clinical outcomes of stereotactic radiosurgery for gangliogliomas: an international multicenter study

Mantziaris

Diamond

Pikis

et al. 2022

Journal of Neurosurgery

View full text Add to dashboard Cite

OBJECTIVE The optimal treatment for recurrent and residual gangliogliomas remains unclear. The aim of this study was to evaluate the safety and efficacy of stereotactic radiosurgery (SRS) in the management of patients with recurrent or residual intracranial ganglioglioma. METHODS This retrospective multicenter study involved patients managed with SRS for ganglioglioma. The study endpoints included local tumor control and tumor- or SRS-related neurological morbidity following treatment. Factors associated with tumor progression and neurological morbidity were also analyzed. RESULTS The cohort included 20 patients (11 males [55%]) with a median age of 24.5 (IQR 14) years who had been managed with SRS for ganglioglioma. Five-year radiological progression-free survival was 85.6%. After SRS, 2 patients (10%) experienced transient neurological deterioration. At a median clinical follow-up of 88.5 (IQR 112.5) months, 1 patient (5%) experienced seizure worsening and 1 (5%) required further resection of the tumor because of radiological progression. No mortality was noted in this series. CONCLUSIONS SRS appears to be a safe and effective treatment option for surgically inaccessible, recurrent, and residual gangliogliomas. In this series, the 5-year progression-free survival rate after SRS was 85.6%. Gross-total resection remains the primary treatment of choice for patients with newly diagnosed or recurrent ganglioglioma. SRS may be considered for patients unfit for surgery and those with surgically inaccessible newly diagnosed, residual, and recurrent lesions.

show abstract

Diagnosis and Therapeutic Management of Ventricular Gangliogliomas: An Illustrated Review

Cited by 2 publications

References 51 publications

Infratentorial Relapsing Neuroglial Tumors in Adults: Management and Unsolved Issues—A Systematic Review

Infratentorial Relapsing Neuroglial Tumors in Adults: Management and Unsolved Issues—A Systematic Review

Radiological and clinical outcomes of stereotactic radiosurgery for gangliogliomas: an international multicenter study

Contact Info

Product

Resources

About